Detalhe da pesquisa
1.
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: U.S. Myeloma Immunotherapy Consortium real world experience.
Haematologica
; 2023 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37855036
2.
Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma.
J Proteome Res
; 20(6): 3134-3149, 2021 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34014671
3.
Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy.
Transplant Cell Ther
; 30(3): 283.e1-283.e10, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38123069
4.
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy.
Blood Adv
; 8(1): 251-259, 2024 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37855718
5.
Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel.
Cancers (Basel)
; 15(19)2023 Sep 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37835405
6.
IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB- and caspase-8-dependent mechanisms.
Blood Adv
; 5(19): 3776-3788, 2021 10 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34464977
7.
Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma.
JCI Insight
; 6(24)2021 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34793338